Objective:

The article examines the objective, findings, and clinical context described in Cefazolin Compared With Antistaphylococcal Penicillins for Methicillin-Susceptible Staphylococcus aureus Infections.

Approach:

• Evidence base: The meta-analysis combined the French CloCeBa and international SNAP trials, including 1,579 patients with 90-day mortality data from 112 hospitals in 9 countries.
• Analysis: It estimated pooled odds ratios and posterior probabilities for mortality and safety outcomes, including noninferiority within a 2.5% absolute mortality-risk margin.

Key Findings:

• For 90-day mortality, cefazolin versus flucloxacillin or cloxacillin had a pooled OR of 0.84 (95% CrI, 0.56-1.28); the posterior probability of noninferiority was 95.5%, and of superiority was 81.0%.
• Adverse-event-related treatment discontinuation was less frequent with cefazolin (OR, 0.25; 95% CrI, 0.13-0.48; absolute risk difference, −6.6%), with a posterior probability of superiority above 98%.
• Acute kidney injury was less frequent with cefazolin (OR, 0.54; 95% CrI, 0.25-0.97; absolute risk difference, −7.9%), also with a posterior probability of superiority above 98%.
• SNAP enrolled patients with penicillin-resistant MSSA; CloCeBa included MSSA regardless of penicillin susceptibility, and approximately 70% of isolates carried blaZ.

Interpretation:

The authors report that randomized-trial findings align with prior observational evidence. Safety results were consistent across both trials, while mortality estimates warrant more caution. The trials support cefazolin noninferiority in a population enriched for penicillinase production, a proposed mechanism of the cefazolin inoculum effect.

Limitations:

• Only two randomized trials were available, and SNAP contributed 82% of participants.
• Between-study heterogeneity could not be estimated reliably; the prior largely determined it.
• Estimated intervals for mortality and acute kidney injury included 1.
• The clinical significance of the cefazolin inoculum effect remains unresolved; relevant trial subgroups were small or still under characterization.

Conclusion:

The randomized evidence found cefazolin noninferior to antistaphylococcal penicillins for 90-day mortality within the prespecified margin, with fewer treatment discontinuations and acute kidney injury. The authors identify the inoculum effect and the potential role of targeted testing in high-burden infections as unresolved questions.

Sources:

• Article context supplied in the prompt